|  | Cancer | Lymphoma

Repeat Bone Marrow Biopsy in Lymphoma: Indications and Clinical Utility

Serial bone marrow biopsies (BMB) are integral to lymphoma management, providing information unattainable by imaging or blood tests alone.

Six Key Indications

  1. Treatment Response Assessment: Compare pre- and post-therapy marrow involvement. Complete remission (CR) requires negative BMB (by morphology and often immunohistochemistry/flow cytometry). Residual involvement indicates partial response or refractory disease.
  2. Minimal Residual Disease (MRD) Detection: Flow cytometry (sensitivity 10⁻⁴–10⁻⁵) or PCR for clonal immunoglobulin/T-cell receptor rearrangements detects MRD after CR. MRD positivity predicts earlier relapse; may guide consolidation (e.g., autologous transplant) or maintenance therapy.
  3. Relapse/Progression Confirmation: New cytopenias, rising LDH, or suspicious imaging. BMB confirms histologic transformation (e.g., indolent → aggressive) or new clone.
  4. Therapy Toxicity Evaluation: Chemotherapy/radiation cause myelosuppression. BMB assesses cellularity, dysplasia, and rules out therapy-related MDS/AML (t-MN).
  5. Prognostic Stratification: Serial MRD kinetics and depth of response (CR vs. CRu vs. PR) inform risk-adapted therapy. Persistent MRD after frontline therapy = high-risk.
  6. Clinical Trial/Translational Research: Mandatory in many protocols for correlative studies (biomarkers, microenvironment, resistance mechanisms).

Procedure Considerations

Posterior iliac crest; local anesthesia ± sedation; core biopsy + aspirate. Complications rare (bleeding, infection, pain). Timing: typically after 2–4 cycles (interim) and end-of-treatment; also at progression.

Lymphoma - Related Articles